PE Anti-WDR4 antibody [EPR11052],Abcam,AB306165
This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
Target Binding Affinity, IHC-P, ICC/IF, Antibody Labelling, Flow Cyt (Intra)
Conjugate
PE
Platform ID
BAB243393673
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Non-catalytic component of the METTL1-WDR4 methyltransferase complex required for the formation of N(7)-methylguanine in a subset of RNA species, such as tRNAs, mRNAs and microRNAs (miRNAs) (PubMed : 12403464, PubMed : 31031083, PubMed : 31031084, PubMed : 36599982, PubMed : 36599985, PubMed : 37369656). In the METTL1-WDR4 methyltransferase complex, WDR4 acts as a scaffold for tRNA-binding (PubMed : 36599982, PubMed : 36599985, PubMed : 37369656). Required for the formation of N(7)-methylguanine at position 46 (m7G46) in a large subset of tRNAs that contain the 5'-RAGGU-3' motif within the variable loop (PubMed : 12403464, PubMed : 34352206, PubMed : 34352207, PubMed : 36599982, PubMed : 36599985, PubMed : 37369656). M7G46 interacts with C13-G22 in the D-loop to stabilize tRNA tertiary structure and protect tRNAs from decay (PubMed : 36599982, PubMed : 36599985). Also required for the formation of N(7)-methylguanine at internal sites in a subset of mRNAs (PubMed : 31031084, PubMed : 37379838). Also required for methylation of a specific subset of miRNAs, such as let-7 (PubMed : 31031083). Independently of METTL1, also plays a role in genome stability : localizes at the DNA replication site and regulates endonucleolytic activities of FEN1 (PubMed : 26751069). See full target information WDR4
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.